[Chemotherapy for non-small cell lung cancer: split-dose administration of Cisplatin over four consecutive days and Vinorelbine ditartrate]
- PMID: 19223742
[Chemotherapy for non-small cell lung cancer: split-dose administration of Cisplatin over four consecutive days and Vinorelbine ditartrate]
Abstract
Purpose: At present, combination chemotherapy with Cisplatin (CDDP) and Vinorelbine ditartrate (VNR) is one of the standard regimens for non-small cell lung cancer (NSLC). To avoid renal damage by CDDP, hydration and diuretic are indicated. But elderly/postoperative patients who have reduced lung vessel capacity are a high-risk group for pulmonary edema/right heart failure by hydration. In our hospital, CDDP is administered on four consecutive days without large hydration.
Material & methods: CDDP: 80 mg/m2 (over four consecutive days)without large hydration+VNR: 20 mg/m2 was administered 30 NSLC patients(Stage III A & IV). Serum concentration of CDDP was monitored.
Result: Response rate was CR: 0 case; PR: 9 cases; SD: 16 cases; PD: 5 cases. Mean survival time (MST) was 292 days. The efficacy and prognosis are equivalent to a conventional CDDP+VNR regimen. On the other hand, side effects were reduced; neutrocytopenia (> Grade 3): 17%, renal dysfunction (>Grade 1): 17%. Mean serum concentrations of CDDP were accumulated day by day, 0.91 microg/mL(Day 1), 2.44 microg/mL(Day 4), but were all under the toxic threshold(8 microg/mL).
Conclusion: Our regimen (CDDP given over four consecutive days without large hydration) may become a regimen for the high-risk patient.
Similar articles
-
Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).Lung Cancer. 2008 Sep;61(3):369-77. doi: 10.1016/j.lungcan.2008.01.010. Epub 2008 Mar 4. Lung Cancer. 2008. PMID: 18308419 Clinical Trial.
-
[Clinical investigation of weekly cisplatin and vinorelbine with concurrent radiation therapy for locally advanced non-small cell lung cancer].Gan To Kagaku Ryoho. 2011 Aug;38(8):1313-6. Gan To Kagaku Ryoho. 2011. PMID: 21829070 Japanese.
-
Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.Jpn J Clin Oncol. 2009 Mar;39(3):158-62. doi: 10.1093/jjco/hyn147. Epub 2009 Jan 12. Jpn J Clin Oncol. 2009. PMID: 19139038
-
Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.Anticancer Res. 2012 Feb;32(2):675-80. Anticancer Res. 2012. PMID: 22287762
-
[Hydration of patients treated with cisplatin: practical investigation and establishment of a protocol].Therapie. 2005 Sep-Oct;60(5):499-505. doi: 10.2515/therapie:2005071. Therapie. 2005. PMID: 16433016 Review. French.
Cited by
-
Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.J Cancer Res Clin Oncol. 2024 Jun 5;150(6):290. doi: 10.1007/s00432-024-05766-7. J Cancer Res Clin Oncol. 2024. PMID: 38836908 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials